Orasure Tech: (NASD: OSUR)
$4.41
0.01 (0.23%)
Volume 258,413
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 4.37 - 4.48 |
| 52wk Low - High | 4.24 - 14.01 |
| Previous Close | 4.40 |
| Avg. Volume | 435,735 |
| Industry | MED PRODUCTS |
| Market Cap | 244.83 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.52 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.54 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
169 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.54 |
| Current Quarter Estimate | -0.16 |
| Most Accurate Estimate | -0.16 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | -0.34 |
| Expected Earnings Growth | 15.00% |
Company Description
OraSure Technologies, Inc. is the market leader for oral fluid diagnostics. The Company develops, manufactures, and markets medical devices and diagnostic products for use by insurance companies, public health agencies, clinical laboratories, physicians' offices, and workplace sites.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.16 | -0.12 | -0.54 | -0.22 |
| Number of Estimates | 2 | 3 | 3 | 4 |
| Low Estimate | -0.16 | -0.13 | -0.55 | -0.34 |
| High Estimate | -0.15 | -0.10 | -0.53 | NA |
| Year Ago EPS | -0.07 | -0.04 | -0.22 | -0.54 |
| EPS Growth | -121.43% | -200.00% | -146.97% | 59.97% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| ORASURE TECH | OSUR | 4.41 | |
|
| CONCEPTUS INC | CPTS | 30.92 | |
|
| ATRICURE INC | ATRC | 9.07 | |
|
| CYTOSORBENTS CP | CTSO | 0.12 | |
|
| INVIVO THERAPT | NVIV | 2.89 | |
|
| TRANS1 INC | TSON | 1.70 | |
|
| ABAXIS INC | ABAX | 45.35 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| ALERE INC | ALR | 26.30 | |
|
| BAXTER INTL | BAX | 72.94 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
OraSure Unveils In-Home HIV test
Oct 12, 2012
OSUR Approval Green-Light's CEMI's OTC Program?
Jul 05, 2012
Report for OSUR
May 07, 2013
Financials
| EPS TTM | -0.34 |
| Sales | 88 |
| Net Income | -22 |
| Price/Earnings | NA |
| Price/Book | 1.53 |
| Price/Cash Flow | NA |
| Price/Sales | 2.78 |
News
OraSure Technologies, Walgreens and Chronic Liver Disease Foundation to Launch Rapid Hepatitis C Testing Initiative in Support of National Hepatitis Testing Day - Globenewswire
May 13, 2013
OraSure Technologies to Webcast Annual Meeting of Stockholders - Globenewswire
May 10, 2013
Tech That Disrupts Our Lives for the Better - TheStreet.com
May 10, 2013
WEALTHMAKERS.COM Issues Bearish Research Reports on OSUR, PYG, RDC, SCHW, SNDK, SWN - M2
May 10, 2013
OraSure Technologies Beats Up on Analysts Yet Again - TheMotleyFool
May 9, 2013
OraSure Technologies Shares Down 46.1% Since SmarTrend's Sell Call (OSUR) - Comtex Smartrend(R)
May 9, 2013
OraSure Announces 2013 First Quarter Financial Results - Globenewswire
May 8, 2013
OraSure Technologies Provides Mixed Guidance - Earningswhispers Earnings Guidance
May 8, 2013
Broker Recommendations
| Current ABR | 1.50 |
| ABR (Last Week) | 1.50 |
| # of recs in ABR | 8 |
| Average Target Price | 11.08 |
| Industry Rank by ABR | 175 out of 265 |
| Rank in Industry | 6 out of 72 |
